Novartis AG ADR (NVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novartis AG ADR (NVS) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.25 Billion) by net assets ($46.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Novartis AG ADR - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Novartis AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Novartis AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PetroChina Co Ltd Class A
SHG:601857
|
0.068x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.060x |
|
Lam Research Corp
NASDAQ:LRCX
|
0.146x |
|
Novartis AG
MX:NVSN
|
0.049x |
|
Roche Holding AG
SW:ROG
|
0.296x |
|
Merck & Company Inc
NYSE:MRK
|
0.151x |
|
HSBC Holdings plc
MX:HBCN
|
N/A |
|
LVMH Moët Hennessy - Louis Vuitton Société Européenne
PA:MC
|
0.118x |
Annual Cash Flow Conversion Efficiency for Novartis AG ADR (1998–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG ADR from 1998 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $46.55 Billion | $19.24 Billion | 0.413x | +3.53% |
| 2024-12-31 | $44.13 Billion | $17.62 Billion | 0.399x | +29.11% |
| 2023-12-31 | $46.75 Billion | $14.46 Billion | 0.309x | +29.09% |
| 2022-12-31 | $59.42 Billion | $14.24 Billion | 0.240x | +7.81% |
| 2021-12-31 | $67.82 Billion | $15.07 Billion | 0.222x | -7.75% |
| 2020-12-31 | $56.67 Billion | $13.65 Billion | 0.241x | -1.79% |
| 2019-12-31 | $55.55 Billion | $13.62 Billion | 0.245x | +35.24% |
| 2018-12-31 | $78.69 Billion | $14.27 Billion | 0.181x | +6.67% |
| 2017-12-31 | $74.23 Billion | $12.62 Billion | 0.170x | +10.97% |
| 2016-12-31 | $74.89 Billion | $11.47 Billion | 0.153x | -0.67% |
| 2015-12-31 | $77.12 Billion | $11.90 Billion | 0.154x | -21.36% |
| 2014-12-31 | $70.84 Billion | $13.90 Billion | 0.196x | +10.89% |
| 2013-12-31 | $74.47 Billion | $13.17 Billion | 0.177x | -13.73% |
| 2012-12-31 | $69.22 Billion | $14.19 Billion | 0.205x | -5.50% |
| 2011-12-31 | $65.94 Billion | $14.31 Billion | 0.217x | +7.63% |
| 2010-12-31 | $69.77 Billion | $14.07 Billion | 0.202x | -4.97% |
| 2009-12-31 | $57.46 Billion | $12.19 Billion | 0.212x | +9.54% |
| 2008-12-31 | $50.44 Billion | $9.77 Billion | 0.194x | +3.88% |
| 2007-12-31 | $49.40 Billion | $9.21 Billion | 0.186x | -11.60% |
| 2006-12-31 | $41.29 Billion | $8.71 Billion | 0.211x | -13.43% |
| 2005-12-31 | $33.16 Billion | $8.08 Billion | 0.244x | +22.89% |
| 2004-12-31 | $33.92 Billion | $6.72 Billion | 0.198x | -9.04% |
| 2003-12-31 | $30.52 Billion | $6.65 Billion | 0.218x | +6.21% |
| 2002-12-31 | $28.41 Billion | $5.83 Billion | 0.205x | +18.36% |
| 2001-12-31 | $25.56 Billion | $4.43 Billion | 0.173x | -15.86% |
| 2000-12-31 | $22.52 Billion | $4.64 Billion | 0.206x | +11.91% |
| 1999-12-31 | $23.55 Billion | $4.33 Billion | 0.184x | -2.48% |
| 1998-12-31 | $22.66 Billion | $4.28 Billion | 0.189x | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more